The Neuroblastoma Program at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center treats infants and young children with newly diagnosed and relapsed or hard-to-treat neuroblastoma, a cancer that begins in nerve tissue. Specialists in our program are renowned for treating the most complex cases, as well as their expertise in delivering leading-edge treatments.
Dana-Farber/Boston Children’s is an integrated pediatric hematology and oncology partnership between Dana-Farber Cancer Institute and Boston Children’s Hospital. We offer, in one specialized program, the full spectrum of services that are needed for diagnosis, treatment and ongoing care of even the rarest and hard-to-treat conditions.
The Neuroblastoma Program is the only center in New England and one of only a few in the country to offer therapy with I-131 MIBG, a compound that is absorbed by certain types of nerve tissue, including neuroblastoma cells. Our physicians use it to deliver targeted radiation therapy to neuroblastoma cells to treat high-risk, relapsed or refractory disease.
Patient care teams include a pediatric oncologist who specializes in the treatment of neuroblastoma and works closely with pediatric surgeons, hematology nurses, pediatric oncology nurse practitioners, imaging specialists, pathologists, and stem cell transplant physicians.
Through our work with the Children’s Oncology Group and the New Approaches to Neuroblastoma Therapy Consortium, we offer the most phase I clinical trials in New England for children with recurrent neuroblastoma.
Learn more about our Neuroblastoma Program on the Dana-Farber/Boston Children’s website.